Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02532010 · ClinicalTrials.gov registry record · Phase 2
Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT02532010 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 13 participants.
The verdict
NCT02532010, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to see if a medicine called pacritinib is both safe and effective as a study intervention for patients with AML in combination with either decitabine or cytarabine. Pacritinib is an experimental drug that is being studied to treat acute myeloid leukemia (AML). Decitabine and cytarabine are both FDA approved drugs that are used in treatment of AML. Pacritinib is being tested in clinical trials and has not been submitted to the U.S. Food and Drug Administration (FDA) for approval for any indications. Pacritinib is a drug that is designed to slow down the growth of leukemic cells.
Interventions
- DRUG Decitabine
- DRUG Cytarabine
- DRUG Pacritinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-06-15 |
| Est. Completion | 2017-10-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02532010
The ClinicalTrials.gov registry entry for NCT02532010 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Decitabine is the first listed.
NCT02532010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02532010 about?
NCT02532010 is a clinical study titled "Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML". The purpose of this study is to see if a medicine called pacritinib is both safe and effective as a study intervention for patients with AML in combination with either decitabine or cytarabine. Pacritinib is an experimental drug that is being studied to treat acute myeloid leukemia (AML). Decitabine...
What is the current status of trial NCT02532010?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2015-06-15. Estimated completion is 2017-10-24.
What interventions are being tested in trial NCT02532010?
The interventions under investigation include: Decitabine (DRUG), Cytarabine (DRUG), Pacritinib (DRUG).
Who is sponsoring clinical trial NCT02532010?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.